The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 37 new drugs in its recent meeting, under the provisions of the Drugs Prices Control Order (DPCO), 2013, including hypertensive medicines, anti-diabetic medicines, among others.
Various formulations and strengths of drugs for which prices has been fixed during the latest meeting include bilastine and montelukast tablets from Cipla Ltd, bisoprolol fumarate and telmisartan tablets from Dr Reddy’s Laboratories, levocetirizine dihydrochloride and montelukast sodium syrup from German Remedies, and myo-Inositol and metformin hydrochloride (SR) tablets from Mankind Pharma, Emcure Pharmaceuticals, and Torrent Pharmaceuticals.
Retail prices of moxifloxacin hydrochloride and ketorolac tromethamine ophthalmic solution from Torrent Pharmaceuticals, multiple electrolytes and 5% dextrose injection type-I USP from Otsuka Pharmaceutical India, pracetamol, phenylephrine hydrochloride and chlorpheniramine maleate tablets from Intas Pharmaceuticals, Stedman Pharmaceuticals, and Macleods Pharmaceuticals, paroxetine (CR) and clonazepam capsules from Ipca Laboratories, dapagliflozin and telmisartan tablets and glycopyrronium, formoterol fumarate, budesonide inhalation suspension from Glenmark Pharmaceuticals, among others.
Earlier, in a meeting on November 27, 2025, the Authority has fixed the retail price of 1 new drugs under the provisions of the Drugs Prices Control Order (DPCO), 2013, including several anti-diabetic, anti-hypertensive, and respiratory medicines.
These are new drugs, under paragraph 2(1)(u) of the Drugs Prices Control Order (DPCO), 2013.
Under the Paragraph 2(1)(u) of the DPCO, 2013, a new drug is defined as a a formulation launched by an existing manufacturer of a drug of specified dosages and strengths as listed in the National List of Essential Medicines (NLEM) by combining the drug with another drug either listed or not listed in the NLEM or a formulation launched by changing the strength or dosages or both of the same drug of specified dosages and strengths as listed in the NLEM.
The methodology of calculating and fixing the retail price of new drugs for existing manufacturers of scheduled formulations are specified in the Para 5 and 15 of the DPCO, 2013, which is followed by the NPPA to arrive at the price against the applications submitted by the companies.
In case the retail price of any of these formulations are not complied with, as per the price notifications and notes released by the authority, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955, added the price regulator.
